Perinatal use of lurasidone for the treatment of bipolar disorder

• Published in: Experimental and clinical psychopharmacology Vol. 30; no. 2; p. 249
• Main Authors: Montiel, Catalina, Newmark, Rebecca L, Clark, Crystal T
• Format: Journal Article
• Language: English
• Published: United States 01.04.2022
• Subjects: Antipsychotic Agents - adverse effects; Bipolar Disorder - drug therapy; Female; Humans; Lurasidone Hydrochloride - therapeutic use; Pregnancy
• ISSN: 1936-2293
• DOI: 10.1037/pha0000509

Atypical antipsychotics are commonly prescribed for the treatment of severe mental illnesses during pregnancy. Evidence regarding the impact of physiologic changes during pregnancy on the concentration of atypical antipsychotics is limited, specifically in the case of lurasidone. Data to guide dosing in pregnancy that maximizes efficacy and minimizes adverse effects are lacking. This case report presents perinatal changes in the concentration of lurasidone and the implications for Bipolar Disorder (BD) illness course in a primiparous woman. Monitoring of lurasidone serum concentrations and recurrence of BD symptoms after the second trimester of pregnancy until the third postpartum month was completed. Lurasidone serum concentrations ranged from 0 to 4.7 ng/mL during pregnancy and increased to 10-12 ng/mL postpartum. The subject presented with worsening anxiety and depressive symptoms during the second trimester of pregnancy which resulted in a 40 mg daily dose increase during the second half of her pregnancy. Despite the decrease in lurasidone to the preconception dose post-delivery, the concentrations were higher postpartum compared to pregnancy. The decrease in lurasidone serum concentrations during pregnancy may increase the risk of worsening BD symptoms and suggests the need for determination of whether therapeutic monitoring and dose titration during pregnancy decreases illness exacerbation. (PsycInfo Database Record (c) 2022 APA, all rights reserved).